K. Pisters, W. Evans, C. Azzoli, M. Kris, C. Smith et al., Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non???Small-Cell Lung Cancer Guideline, Journal of Clinical Oncology, vol.25, issue.34, pp.5506-5524, 2007.
DOI : 10.1200/JCO.2007.14.1226

A. Depierre, J. Lagrange, S. Theobald, P. Astoul, P. Baldeyrou et al., Options and Recommendations for the management of nonsmall cell lung carcinoma patients, Bull Cancer, vol.90, pp.151-66, 2003.

J. Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd et al., Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group, Journal of Clinical Oncology, vol.26, issue.21, pp.3552-3561, 2008.
DOI : 10.1200/JCO.2007.13.9030

J. Douillard, R. Rosell, D. Lena, M. Ramlau, R. Gonzáles-larriba et al., Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB???IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial, The Lancet Oncology, vol.7, issue.9, pp.719-746, 2006.
DOI : 10.1016/S1470-2045(06)70804-X

C. Butts, K. Ding, L. Seymour, P. Twumasi-ankrah, B. Graham et al., Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non???Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10, Journal of Clinical Oncology, vol.28, issue.1, pp.29-34, 2010.
DOI : 10.1200/JCO.2009.24.0333

R. Arriagada, B. Bergman, A. Dunant, L. Chevalier, T. Pignon et al., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer, N Engl J Med, vol.350, pp.351-60, 2004.

A. Bezjack, C. Lee, K. Ding, M. Brundage, T. Winton et al., Quality-of-Life Outcomes for Adjuvant Chemotherapy in Early-Stage Non???Small-Cell Lung Cancer: Results From a Randomized Trial, JBR.10, Journal of Clinical Oncology, vol.26, issue.31, pp.5018-5027, 2008.
DOI : 10.1200/JCO.2007.12.6094

F. Barlesi, K. Barrau, C. Doddoli, S. Morange, X. Thirion et al., Essai randomis?? de phase III de chimioth??rapie adjuvante par CDDP/docetaxel versus CDDP/gemcitabine dans les cancers bronchiques non ?? petites cellules r??s??qu??s avec la qualit?? de vie comme objectif principal, Revue des Maladies Respiratoires, vol.23, issue.5, pp.489-96, 2006.
DOI : 10.1016/S0761-8425(06)71825-3

N. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull et al., The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-76, 1993.
DOI : 10.1093/jnci/85.5.365

B. Bergman, N. Aaronson, S. Ahmedzai, S. Kaasa, and M. Sullivan, The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials, European Journal of Cancer, vol.30, issue.5, pp.635-677, 1994.
DOI : 10.1016/0959-8049(94)90535-5

D. Osoba, B. Zee, J. Pater, D. Warr, L. Kaizer et al., Psychometric properties and responsiveness of the EORTC Quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer, Quality of Life Research, vol.16, issue.5, pp.353-64, 1994.
DOI : 10.1007/BF00451727

M. Goodyear and M. Fraumeni, Incorporating quality of life assessment into clinical cancer trials Quality of Life and Pharmacoeconomics in Clinical Trials, pp.1003-1016, 1996.

M. King, The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30, Quality of Life Research, vol.311, issue.6, pp.555-67, 1996.
DOI : 10.1007/BF00439229

D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater, Interpreting the significance of changes in health-related quality-of-life scores., Journal of Clinical Oncology, vol.16, issue.1, pp.139-183, 1998.
DOI : 10.1200/JCO.1998.16.1.139

S. Park, I. Kim, K. Baek, S. Lee, W. Chang et al., Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer, Annals of Oncology, vol.24, issue.6, pp.1630-1639, 2013.
DOI : 10.1093/annonc/mds649

P. Yang, A. Cheville, J. Wampfler, Y. Garces, A. Jatoi et al., Quality of Life and Symptom Burden among Long-Term Lung Cancer Survivors, Journal of Thoracic Oncology, vol.7, issue.1, pp.64-70, 2012.
DOI : 10.1097/JTO.0b013e3182397b3e

C. Belani, J. Pereira, J. Von-pawel, A. Pluzanska, V. Gorbounova et al., Effect of chemotherapy for advanced non-small cell lung cancer on patients??? quality of life, Lung Cancer, vol.53, issue.2, pp.231-240, 2006.
DOI : 10.1016/j.lungcan.2006.05.003

M. Wislez, F. Barlesi, B. Besse, J. Mazières, P. Merle et al., Customized Adjuvant Phase II Trial in Patients With Non???Small-Cell Lung Cancer: IFCT-0801 TASTE, Journal of Clinical Oncology, vol.32, issue.12, pp.1256-61, 2014.
DOI : 10.1200/JCO.2013.53.1525

G. Scagliotti, U. Pastorino, J. Vansteenkiste, L. Spaggiari, F. Facciolo et al., Randomized Phase III Study of Surgery Alone or Surgery Plus Preoperative Cisplatin and Gemcitabine in Stages IB to IIIA Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.30, issue.2, pp.172-180, 2012.
DOI : 10.1200/JCO.2010.33.7089

E. Felip, R. Rosell, J. Maestre, J. Rodríguez-paniagua, T. Morán et al., Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non???Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.28, issue.19, pp.3138-3183, 2010.
DOI : 10.1200/JCO.2009.27.6204

K. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. André et al., DNA Repair by ERCC1 in Non???Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy, New England Journal of Medicine, vol.355, issue.10, pp.983-91, 2006.
DOI : 10.1056/NEJMoa060570

P. Sève and C. Dumontet, Is class III ??-tubulin a predictive factor in patients receiving tubulin-binding agents?, The Lancet Oncology, vol.9, issue.2, pp.168-75, 2008.
DOI : 10.1016/S1470-2045(08)70029-9